Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $205.00 USD
Change Today +1.88 / 0.93%
Volume 1.1M
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5200 Illumina Way

San Diego, CA 92122

United States

Phone: 858-202-4500

Fax: 858-202-4766

Illumina, Inc. provides sequencing-and array-based solutions for genetic analysis worldwide. The company’s portfolio of integrated systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its sequencing instruments could perform a range of nucleic-acid (deoxyribonucleic acid (DNA) and RNA) analyses across a range of sample sizes. To provide the company’s customers with sample-to-answer solutions, the company owns various companies, such as NextBio, which provides clinical and genomic informatics; Advanced Liquid Logic Inc., which provides digital microfluidics and liquid handling solutions; and Epicentre Technologies Corporation, a provider of nucleic-acid sample preparation reagents and specialty enzymes for sequencing and array applications. The company also owns Verinata Health, Inc. and BlueGnome Ltd. The acquisition of Verinata Health, Inc. (Verinata) strengthened the company’s reproductive health portfolio by adding the Verinata verifi prenatal test, a noninvasive prenatal test (NIPT) for high-risk pregnancies. The company’s acquisition of BlueGnome Ltd., a provider of genetic solutions for screening chromosomal abnormalities and genetic variations associated with developmental delay and infertility, expanded its ability to offer integrated solutions in reproductive health and cancer. The company also provides products and services for other life sciences applied markets, such as agrigenomics. Government and corporate researchers use the company’s sequencing and array-based tools to accelerate and improve agricultural research. Principal Products and Technologies Sequencing The company’s portfolio of sequencing platforms represents a family of systems that sets the standard for productivity, cost-effectiveness, and accuracy among next-generation sequencing technologies. Customers use the company’s platforms to perform whole-genome, de novo, and exome sequencing, and targeted resequencing of specific gene regions and genes. The company’s DNA sequencing technology is based on its proprietary reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis (SBS) biochemistry. SBS tracks the addition of labeled nucleotides as the DNA chain is copied in a massively parallel fashion. The company’s SBS sequencing technology provides researchers with a range of applications and the ability to sequence even large mammalian genomes in days rather than weeks or years. The company’s sequencing platforms could generate between 500 megabases and 1.8 terabases (equivalent to 16 human genomes) of genomic data, depending on the instrument and application. There are different price points per gigabase for each instrument, and for different applications, which range from small-genome, amplicon, and targeted gene-panel sequencing to population-scale whole human genome sequencing. Arrays Arrays are used for a range of DNA and RNA analysis applications, including single nucleotide polymorphism (SNP) genotyping, copy number variation analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of approximately 5,000,000 known genetic markers on a single array. The company’s BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that could perform various assays simultaneously. This facilitates large-scale analysis of genetic variation and biological function in a flexible manner. Using its BeadArray technology, the company achieves high-throughput analysis through a high density of test sites per array and the ability to format arrays in various configurations. The company’s HiScan and iScan array scanner systems, and its NextSeq 550 system, which the company announced in January 2015, image the arrays. Consumables The company has developed various library preparation and sequencing kits to simplify workflows and accelerate analysis. The company’s sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which could sequence exomes, speci

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $205.00 USD +1.88

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $132.64 USD +3.05
Dr Reddy's Laboratories Ltd 3,643 INR +23.45
Hologic Inc $35.05 USD +0.09
Sigma-Aldrich Corp $139.08 USD -0.01
Waters Corp $133.29 USD -0.55
View Industry Companies
 

Industry Analysis

ILMN

Industry Average

Valuation ILMN Industry Range
Price/Earnings 70.8x
Price/Sales 14.9x
Price/Book 18.2x
Price/Cash Flow 62.7x
TEV/Sales 13.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.